• News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • FREE newsletter subscription
  • Search
  • Menu Menu
International Hospital
  • AI
  • Cardiology
  • Oncology
  • Neurology
  • Genetics
  • Orthopaedics
  • Research
  • Surgery
  • Innovation
  • Medical Imaging
  • MedTech
  • Obs-Gyn
  • Paediatrics

Archive for category: Featured Articles

Featured Articles

Non invasive techniques for detecting vulnerable plaques

, 26 August 2020/in Featured Articles /by 3wmedia

Rupture of the coronary plaque surface, accompanied by the exposure of thrombogenic, red cell-rich necrotic core material, is one of the most important underlying mechanisms in acute coronary syndrome (ACS). After decades of idling, such plaques sometimes suddenly burst into this life-threatening condition. The rupturing occurs during the evolution of coronary atherosclerotic lesions, and is often accompanied by super-imposed thrombosis.
To date, the precise mechanisms involved in plaque erosion remain generally unknown. Coronary spasm is simply a universal suspect.
Prevention is therefore considered to be the only effective means for reducing the mortality and morbidity of coronary heart disease.
Coronary lesions that are prone to rupture have a distinct morphology compared with stable plaques, and provide a unique opportunity for non-invasive imaging to identify vulnerable plaques, before they lead to clinical events.

Plethora of terminology
The severity and prognosis of plaque rupture is characterized by a plethora of terminology. Plaque vulnerability describes the risk of symptomatic thrombosis in the short term, whereas plaque ‘activity’ remains ambiguous (referring to one of a wide variety of processes associated with progression).
‘Plaque burden’ is accepted to denote extent of disease. It is a measure of the extent of atherosclerosis, regardless of the cellular composition or activity of plaques. There are various ways to measure the burden: plaque volume, lesion-coverage of arterial surface – sometimes based on using computed tomography (CT) to measure coronary calcium score, or ultrasound to assess plaque area in the carotid bed. Given that atherosclerosis is multi-focal (and impacts upon the entire vasculature), a high plaque burden in one region (e.g. the lower limbs) may be a marker for advanced disease elsewhere. The highest concern on the latter consists of the coronary arteries due to their high degree of susceptibility.

Size is not everything
Rather than plaque size alone, the risk of rupture depends more on the composition and type of plaque, inter alia, richness in soft extracellular lipids – and macrophages. Indeed, structurally what is required for plaque rupture is an extremely thin fibrous cap. As a result, ruptures are usually minuscule and occur mainly at the periphery of the cap covering the lipid-rich core – among lesions clinically defined as thin-cap fibroatheromas. They have reduced tensile strength and are more extensible than intact caps, while the presence of collagen and smooth muscle cells is lower. In effect, as extracellular lipid accumulation progresses (usually due to external stress/triggers), the fibrous cap weakens and predisposition of a plaque to rupture increases.
Several other factors are also believed to play a concurrent role, among them inflammatory cell recruitment, macrophage formation, necrosis, matrix synthesis, calcification, arterial remodelling, etc.
The interaction between these factors is not only complex but variable too, as far as the development of plaque is concerned. This leads to unpredictable rates of progression and variable clinical outcomes.

Not all ruptures lead to ACS
Nevertheless, there are, once again, certain other issues in play with regard to the clinical relevance of vulnerable plaque detection. Most plaques remain subclinical and asymptomatic. Others elicit acute thrombosis and may lead to an acute coronary syndrome (ACS).
However, not all plaque ruptures cause ACS. Some develop obstructively (stable angina). Indeed, on its own, stable angina pectoris derived from atherosclerosis is rarely fatal without scarring of the myocardium – the latter can provoke an arrhythmia presenting as sudden cardiac death.
Confusion arises in other contexts too. For example, the presence of thrombosis is not the same as the occurrence of ACS. Indeed, some physicians believe that the majority of ruptures and erosions are asymptomatic in the short term, although they may sometimes lead to gradual coronary narrowing.

Nightmare for prognosis
This lack of clarity has proven to be a nightmare. ACS occurs only when vulnerable plaque, platelet activation and impaired fibrinolysis occur alongside inflammatory states. Such vulnerability may change with time, and it is these changing dynamics vis-a-vis stress/triggers which determines the exact moment and point of rupture.  As a result, the non-invasive detection of vulnerable plaques is considered to be of great clinical relevance, especially in ultra-high risk patients.

At the cutting-edge
Currently, a host of new, non-invasive techniques are being harnessed to assess and predict the likelihood of coronary plaque rupture. Leading the way are computational fluid dynamics (CFD) and fractional flow reserve (FFR) methodologies. They are based on harnessing supercomputing capability to the analysis of CT angiography.
The high quality imaging and sub-millimetre resolution of modern computed tomography (CT) scanners allows characterization and quantification of lesions at accuracies unimaginable barely a decade ago. CFD supplements the functional information of CT-based plaque assessment by calculating lesion-specific endothelial shear stress and FFR. Such supplementation of functional information by quantified morphologic data about coronary plaques is considered to be one of the best means to detect vulnerable plaques.

FFR guided therapy
For patients with coronary calcification and hemodynamically significant obstructive disease, FFR has long been considered the best solution for guiding re-vascularization of lesions and improving outcomes. FFR provides an index of atherosclerosis and lesion significance, as measured with a pressure-sensitive angioplasty guidewire. FFR-guided therapy has improved patient outcomes, reduced stent insertions. However, it is used in less than one-tenth of cases due to procedural and operator related factors – above all, patient discomfort due to time and motion artifact as well as cost.

Coupling FFR to CT angiography
More recently, due to the developments in non-invasive CT imaging and the application of CFD modelling to CT angiography datasets, FFR can be derived non-invasively without requiring modification of standard CT angiography acquisition protocols or inducing hyperemia.
Such non-invasive FFR, moreover, has been shown to demonstrate excellent correlation with invasive FFR.

PLATFORM Study
One of the key studies investigating the impact of combining FFR and CT was called PLATFORM (the Prospective LongitudinAl trial of FFRCT: Outcome and Resource Impacts).
PLATFORM, which ran from the end of 2013 to 2015 at centres in the US and Europe, demonstrated improved patient selection for invasive angiography using a combination of coronary CT angiography (CCTA) along with fractional flow reserve CT (FFRCT). The so-called CCTA-FFRCT approach increased the chance of identifying obstructive coronary artery disease among those intended for invasive testing and held forth the promise of serving as an efficacious gatekeeper to invasive coronary angiography (ICA). 
The findings were conclusive, with numbers presented by researchers at the European Society of Cardiology at London in 2015. The use of FFRCT in patients with planned invasive catheterization, they noted, was associated with a reduction in the rate of finding no obstructive CAD at ICA, from 73% to 12%. It also resulted in cancellation of 61% of ICAs.

Computational fluid dynamics
In effect, the adoption and translation of CFD modelling may be considered to have revolutionized cardiovascular medicine.
CFD is a specialist IT discipline bringing together advanced mathematics and fluid mechanics. Its roots lie in mission-critical/high-performance engineering systems. Much of its history is intimately connected to the aerospace industry, to enhance the accuracy of complex simulation scenarios such as transonic or turbulent air flows.
In medicine, the first-ever CFD investigations began in cardiovascular research, to clarify the characteristics of aortic flow in a degree of detail below the threshold of experimental measurements. Computer-aided design (CAD) models of the human vascular system were built using modern imaging techniques, coupled to rapid, economical, low-risk 3-D prototyping. The ensuing models precisely computed factors such as blood flow and tissue behaviour and response, taking close consideration of boundary conditions such as complex systemic/physiological pressure and ‘virtualized’ metrics such as wall shear stress.

CFD modelling has already revolutionized the development of devices such as stents, valve prostheses, and ventricular assist devices.
CFD is currently being translated into cardiovascular clinical tools for minimally-invasive application to a wide spectrum of coronary, valvular, myocardial and peripheral vascular diseases. One of the biggest advantages offered by combining high-resolution imaging with CFD is that unique patient-specific data can be juxtaposed into multi-scale, variable duration models to make individualized risk prediction and planning possible. This is directly opposed to registry-based, population-averaged data.
In the future, it is expected that the trend to ‘digital patient’ representation, combined with population-scale numerical models, will reduce cost, time and risk associated with clinical trials.

The massive processing power brought to play by CFD quickly led to the understanding that mechanistic forces of arterial wall shear stress (WSS) and axial plaque force acting on coronary plaques might be responsible for both the development of coronary plaque and its vulnerability to rupture.
For example, it is difficult to measure WSS, a key factor in the development of atherosclerosis and in-stent restenosis, without invasive procedures – with all the latters’ attendant risks and frequent futility. One study demonstrated that less than a third of patients with suspected obstructive coronary artery disease (CAD) showed its presence after invasive coronary angiography (ICA), while an even-smaller number had flow-limiting obstructive disease based on invasive fractional flow reserve (FFR).
In contrast, CFD models can both compute and map the spatial distribution of WSS, establishing links between haemodynamic disturbance and atherogenesis and explaining why atherosclerotic plaque tends to be deposited at arterial bends or bifurcations.
CFD modelling has also been central to comprehending the role of WSS in endothelial homoeostasis. While turbulent blood flow reduces WSS and stimulates adverse vessel remodelling, non-disturbed laminar blood flow seems to be associated with higher WSS – which reduces endothelial cell activation. In a March 2012 issue of ‘Circulation’, researchers from  Johns Hopkins University School of Medicine, CVPath Institute at Maryland and the Mount Sinai School of Medicine in New York established that a complex series of WSS-related signalling pathways and interactions underlie the above phenomenon.
Though much more remains to be understood before such pathways can be exploited to their full extent to yield new anti-atherosclerotic therapies, few doubt that the way forward lies in further CFD models that combine dynamic fluid behaviour analysis with cellular response.

Other emerging techniques
Apart from CFD, other methodologies under consideration to quantify measurement of coronary plaque and lesions include the use of radio-frequency (RF) backscatter intravascular ultrasound. A prospective study in 2011 in the US known as ATLANTA sought to make the first-ever assessment of the accuracy of 3-dimensional, quantitative measurements of coronary plaque by computed tomography angiography (CTA) against intravascular ultrasound with radiofrequency backscatter analysis (IVUS/VH).
For the ATLANTA study, 60 patients underwent coronary X-ray angiography, IVUS/VH and coronary CTA. Plaque geometry and composition was quantified after spatial co-registration on segmental and slice-by-slice bases. The researchers found significant correlation for all pre-specified parameters by segmental and slice-by-slice analyses. Compositional analysis suggested that high-density non calcified plaque on CTA best correlated with fibrous tissue and low-density non calcified plaque correlated with necrotic core plus fibrofatty tissue by IVUS/VH.

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:17:292021-01-08 12:30:34Non invasive techniques for detecting vulnerable plaques

Strong presence of Nordic skills and innovations in life science at Arab Health 2018

, 26 August 2020/in Featured Articles /by 3wmedia

Danish, Finnish and Swedish organizations join forces to facilitate business partnering and networking at Arab Health 2018. At the event, 75 Nordic companies bring innovative life science solutions aiming to add sustainable value to the Middle East healthcare sectors and to build lasting relations between the Nordic participants and local stakeholders.

Business Finland, Business Sweden, Danish Health Tech Group and Global Pharma Consulting are coordinating four national pavilions at Arab Health 2018. To kick off the trade fair, the organizations announce an exclusive Nordic Business Partnering and Networking Reception for invited guests on Monday 29 January 2018 at 7-10 pm at the Sofitel Dubai Downtown.
“This is the only opportunity for stakeholders in the MENA region to talk to so many decision makers, officials and experts from the Nordics in one place in a relaxed setting,” explains Senior Consultant Paula Hassoon at Global Pharma Consulting, organizer of The Innovation Pavilion by Sweden.
“Joining forces with our Danish and Finnish colleagues to host a Nordic partnering and networking event brings added value to all of the participating companies,” she says.

Digital health from Finland
At the four national pavilions, the Nordic companies will showcase cutting-edge med-tech solutions and technologies to the MENA region. According to Meria Heikelä, Director at Business Finland and co-organiser of the Finnish pavilion, Finland ranks among the three strongest health technology economies in the world, with digital health being its largest high-tech export.
“Finland’s world-class research and technology competencies are the pinnacle of its health sector and one reason why Finland has one of the most efficient healthcare systems in the world. Preventive healthcare and rehabilitation solutions are among the key focus areas of Finland at Arab Health 2018,” explains Meria Heikelä.

Danish innovations in med-tech
With the annual Pavilion of Denmark at Arab Health and a recent business delegation visit to UAE and Saudi Arabia healthcare sectors, Danish Health Tech Group is committed to share the Danish med-tech strengths with stakeholders in the MENA region.
“In Denmark, we prioritize design and quality, and innovate through an inherent focus on public-private sector cooperation and by proactively involving patients and staff in the healthcare sector,” says Thomas Andersen, Head of Danish Health Tech Group.

Swedish world-class healthcare
While all the Danish companies are exhibiting with Danish Health Tech Group, Sweden offers two different pavilions.
The Innovation Pavilion by Sweden and the official Swedish pavilion each has representatives from 20 Swedish healthcare and life science companies.
“Sweden is known for its world-class’ innovations within the healthcare sector. Much of this success derives from the tradition of entrepreneurship through the close collaboration between the government, academia and industry,” says Fredrik Bodin, Trade Commissioner of Sweden to the UAE, co-organizer of the official Swedish pavilion.

The national pavilions at Arab Health 2018

  • The Innovation Pavilion by Sweden, organized by Global Pharma Consulting, located at Za’abeel Hall 6 Z6.E30
  • The Finnish Pavilion, co-organized by Business Finland and Business Oulu, located at Hall H3 A10
  • The Pavilion of Denmark, organized by Danish Health Tech Group, two pavilions located at Trade Center Arena SA.F50-59 and Za’abeel Hall 6 Z6.E30
  • The official Swedish pavilion, organized by Business Sweden and the Embassy of Sweden in Abu Dhabi, located at Za’abeel Hall 1, Z1.G50

More information to be obtained from:
Business Finland (Finpro) at www.finpro.fiBusiness Sweden’s at www.business-sweden.seDanish Health Tech Group at www.dk-healthtech.comGlobal Pharma Consulting at www.globalpharma.se

https://interhospi.com/wp-content/uploads/sites/3/2020/08/Photo-Networking-Arab-Health-2017.jpg 533 800 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:17:292021-01-08 12:30:16Strong presence of Nordic skills and innovations in life science at Arab Health 2018

CMEF Spring is part of the world’s largest healthcare event: the Health Industry Summit (tHIS)

, 26 August 2020/in Featured Articles /by 3wmedia

The Health Industry Summit (tHIS) 2017 hosted by China and organized by Reed Sinopharm, was held in Shanghai at the National Exhibition and Convention Center from May 15th to 18th with well over 200,000 healthcare industry professionals from more than 150 countries and regions in attendance.

Now in its third edition, tHIS has been firmly established as the world’s largest health industry event with over 350,000 square meters of exhibition space and 160 individual events and conferences.  It comes at a crucial time as China drives forward its “Healthy China 2030 Plan” initiative to realize among other goals an industry growth target of RMB 16 trillion (USD 2.3 trillion, Euro 1.9 trillion) by 2030 and an increase of average citizen lifespan by 3 years to 79 years.

Key events at tHIS 2017 included China’s three top medical equipment and pharmaceutical exhibitions (CMEF, PHARMCHINA and API China) and the leading healthcare investment forum – Healthcare China 2017. This year’s investment forum was co-organized by Reed Sinopharm, JP Morgan Asset management, CICC and Sinopharm Capital and was attended by more than 1000 CEOs, investors and institutions.

The exhibition featured the entire industry value chain and showcased tens of thousands of the latest technologies and products. Emerging technologies such as VR, AR, wearables and AI featured strongly on the show floor as well as in the key forums. During tHIS 2017, the World Medical Robots Innovation and Development Summit was held to reflect the growing trend for robotics and AI applications.

Over 7000 exhibiting companies from 30 countries were at the show including medical device giants like GE, United Imaging, Siemens, Philips and Mindray as well as major pharmaceutical groups in China including Sinopharm, Shanghai Pharma and CR Pharmaceuticals.  The majority of the most innovative companies in the medical field choose CMEF as their global or Asia Pacific new product launch platform and more than 600 new product launches took place during the 4 days of the show. Among the new products released, United imaging launched its uVR 4D vision explorer platform, enabling more detailed dissect structure and spatial information, while GE launched its first cloud-based digital application for medical equipment management APM (asset performance management), which was developed by their China team. BGI also attended with their gene sequencer BGISEQ-500, a benchtop high-throughput open sequencing platform that provides end-to-end solutions.
Natural Health and Nutrition Expo were among the fastest growing segments in the portfolio, helped by the expected population boom in light of the reversal of the single child policy last year as well as a growing health-conscious middle class in China. Popular international brands like Blackmores, Nature Made and Garden of Life made their debut at the show along with 700 suppliers of health food and supplements, bringing with them popular product lines tailored to the Chinese market.

The Health Industry Summit is organized by Reed Sinopharm, a joint venture between the world’s leading event organizer Reed Exhibitions and China’s leading state-owned medical & pharmaceutical group Sinopharm, ranked number 199 on the latest Fortune 500 list released in July. Its next edition will be held in April 2018 in Shanghai while the 78th China International Medical Equipment Fair (CMEF Autumn 2017) is to take place in Yunnan at the Kunming Dianchi Convention & Exhibition Centre from October 29 to November 1.

Visitor profile
The vast majority of visitors naturally came from China, covering all regions and healthcare sectors. However, there was also a growing segment of international visitors. Topping the list of foreign countries was India with a 20% share of international attendees followed by Korea (15%), Pakistan, Japan, USA, Russia and Germany.

Overall, CMEF visitors spanned the entire medical area – both healthcare and medical device industry. Distributors of medical devices constituted the largest single visitor group with 45% of the total followed by hospital build and design (26%) and rehabilitation centre professionals (see detailed visitor composition chart on previous page).

National pavilions

The international participation is increasing, reflecting the growing importance of China’s healthcare industry. Further adding to the show’s attraction, a large number of national pavilions were featured in a dedicated hall where a constant stream of visitors could view the latest products and technology of companies from countries as diverse as Switzerland, Canada, Taiwan or Germany. For the first time the US and Pakistan had country group exhibits while the Spanish Medical Technology Association (FENIN) led some Spanish companies to make their appearance at the CMEF Spanish pavilion and the German Land of Thuringia organized a regional exhibit for the first time.

https://interhospi.com/wp-content/uploads/sites/3/2020/08/Graph_crop.jpg 446 1000 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:17:292021-01-08 12:30:25CMEF Spring is part of the world’s largest healthcare event: the Health Industry Summit (tHIS)

Premium quality feather cutting instruments

, 26 August 2020/in Featured Articles /by 3wmedia
https://interhospi.com/wp-content/uploads/sites/3/2020/08/47192-Feather-Safety-Razor_IHE_Nov2017.jpg 1500 1027 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:17:292021-01-08 12:30:23Premium quality feather cutting instruments

MEDICAL FAIR ASIA 2018: Future-ready products and industry-leading conferences & forums

, 26 August 2020/in Featured Articles /by 3wmedia

MEDICAL FAIR ASIA 2018, is set to continue its growth path with its 12th edition. An expected 1,000 exhibitors from 50 countries and 20 national pavilions will grace the exhibition to be held in Singapore from 29th to 31st August. Visitors will get to source from a comprehensive range of more than 5,000 products ranging from digital health technology, electromedical equipment, rehabilitation supplies to consumables.

There will be a total of 20 National Pavilions and Country Groups, this edition will see debut group participations from Belgium, Brazil, the Netherlands, Iran, Denmark, European Union Business Avenue, Russia, Spain and Qatar, adding to the internationality of the exhibition.

Inaugural Community Care Pavilion
On the show floor, visitors can also expect to see products relating to the current healthcare trends and needs of the Asian region. The debuting Community Care Pavilion, with its keen focus on geriatrics and digital health technology seeks to address the healthcare needs of both the ageing population and the region’s remote population by bringing healthcare beyond traditional healthcare institutions and into the community. Exhibitors have already arranged for product launches to take place during the 3-day period. France Bed Co Ltd will be showcasing their unique powered turning bed. It features an automatic turning support function that prevents users from bed sores. Xiaoniu Health Co Ltd will be unveiling their intelligent sleep machine that can perform both CPAP and AutoCPAP to sleep apnea patients. 

Another first on the show floor is the inaugural Start-Up Park. Providing a platform for young and exciting start-ups, the exhibits will feature products that could transform the market in the near future including the latest innovations in big data, and IoT. Australian start-up Rapid Response Revival Research will unveil a prototype of their phone case defibrillator, CellAED, the world’s smallest, lightest and first truly mobile AED (Automatic External Defibrillator) for the very first time.

Conferences and forums
Back by popular demand, the exhibition will play host to the second edition of the MEDICINE + SPORTS Conference. This benchmark event for sports medicine will discuss topics ranging from digital innovations in sports and healthcare, exercise medicine to tailored exercise programmes for patients and athletes. A stellar lineup of speakers including experts Dr. Paul Gastin, Director for the Centre for Sport Research at Deakin University, Mr. Christian Stammel, CEO of WT | Wearable Technologies and Prof. James S. Skinner, Professor Emeritus in the Department of Kinesiology, Indiana University, have been confirmed.

With Start-Ups and SMEs deepening their presence in global business, the exhibition will also host the Medtech SME Workshop. Organized by the first and only regional medical technology association, Asia Pacific Medical Technology Association (APACMed), the workshop will provide small businesses with concise knowledge on clinical trials, product validation, patent laws and many others. Through this workshop, Medtech start-ups and SMEs can learn to navigate processes to develop cost-effective solutions to meet the region’s healthcare needs.

In line with the highlight on Community Care, the exhibition will also feature the first-ever Paradigm Shifts in Healthcare seminar from 30th to 31st August. Leading speakers will discuss the evolution of the healthcare industry while attendees learn how to overcome future challenges as healthcare goes beyond hospitals to the community. 

Supported by the Robotic Surgery Society of Singapore, the Medical Innovation & Technology Forum will focus on robotic surgery and discuss how patients evolve from passive healthcare recipients to active value-seekers, encouraging healthcare providers to tap into the latest technological advances to provide more efficient treatment options.

www.medicalfair-thailand.com
https://interhospi.com/wp-content/uploads/sites/3/2020/08/NJD_0733.jpg 533 800 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:17:292021-01-08 12:30:10MEDICAL FAIR ASIA 2018: Future-ready products and industry-leading conferences & forums

IHF Journal – World Hospitals and Health Service

, 26 August 2020/in Featured Articles /by 3wmedia
https://interhospi.com/wp-content/uploads/sites/3/2020/08/IH164_IHF_page1.jpg 1500 986 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:17:292021-01-08 12:30:18IHF Journal – World Hospitals and Health Service

Kimes, March 15-18 2018, Seoul, Korea

, 26 August 2020/in Featured Articles /by 3wmedia
https://interhospi.com/wp-content/uploads/sites/3/2020/08/47216_KIMES-2018_IHE.jpg 1000 685 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:17:292021-01-08 12:30:29Kimes, March 15-18 2018, Seoul, Korea

Pre-hospital, Hospital, Homecare

, 26 August 2020/in Featured Articles /by 3wmedia
https://interhospi.com/wp-content/uploads/sites/3/2020/08/47258_691703-B-2017_17_01_Eagle_Dv2_QtrPageRT-NEW.jpg 1462 1012 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:17:292021-01-08 12:30:21Pre-hospital, Hospital, Homecare

KIMES, Seoul, 15-18 March 2018

, 26 August 2020/in Featured Articles /by 3wmedia
https://interhospi.com/wp-content/uploads/sites/3/2020/08/47218_KIMES-2018_IHE.jpg 1500 1030 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:17:292021-01-08 12:30:22KIMES, Seoul, 15-18 March 2018

Carotid artery stenting – the challenge of plaque protrusion

, 26 August 2020/in Featured Articles /by 3wmedia

Although not commonplace, carotid artery stenting (CAS) is occasionally accompanied by the protrusion of plaque into the stent lumen, and a variety of ischemic complications during intra- and post-operative periods. Among these complications, plaque protrusion (PP) into the stent and thrombus on the stent after CAS are some of the most worrying for clinicians.
The correction of PP is achieved by additional post-dilations or stent-in-stent implantation.

First noticed in mid-1990s
The first observations of PP date over two decades and provided the impetus for embolic protection devices. In a paper published in the mid-1990s, a team led by Frank Veith, M.D (from the Mayo Clinic) suggested that restoration of flow and removal of protection devices might lead to the continuing break off of protrusions and provoke some delayed strokes.
Today, apart from PP, key causes of late in-stent stenosis seen in CAS include neo-intimal proliferation due to self-expanding stents as well as restricted post-procedural stent dimensions from inefficient balloon dilation.

The covered stent
One way to prevent PP is by covering the plaque with a stent graft. Covered stents also offer advantage in usability, without the need for distal protection devices in difficult internal carotid arteries, where a protection filter may be near-impossible to place. However, covered stents are accompanied by a high rate of restenosis. In one randomized trial in the mid-2000s, researchers at Vienna Medical University reported a 38% restenosis rate in patients treated with covered stents for carotid artery stenosis, while restenosis was absent in the bare stent group. The precise causes of high restenosis rates with stent grafts require further research. One suspected factor is the buckling of a covered stent’s proximal and distal ends and the prevention of endothelization.

Both symptomatic and asymptomatic events
During stent implantation, plaque disruption and distal migration of plaque particles may cause symptomatic or asymptomatic ischemic events, in spite of protection devices. These can be viewed on diffusion-weighted (DW) magnetic resonance imaging (MRI).
In some CAS cases, physicians encounter plaque particles filling filters leading to symptomatic cerebral embolism. This is particularly true with ulcerated plaque and severe stenosis.  What is now of growing concern is that, after stent implantation, plaque protrusion into the lumen can lead to peri-procedural stent thrombosis, 30-day stroke, and late in-stent stenosis.

Stroke biggest complication
The biggest complication with carotid artery stenting is stroke. This can occur during CAS and for up to 30 days after the procedure. Although the cause of late stroke after CAS remains unknown, PP is generally suspected to be a key cause.
PP incidence is evaluated by IVUS (intra-venous ultrasound) and angiography, although as we shall see, there are variations in results based on methodology. The prognosis of PP (over a 30-day period) and the incidence of ischemic lesions (48 hours after CAS) are usually assessed by diffusion-weighted images.

The Tokai study
In recent years, one oft-cited report concerns a study by the Department of Cardiology at Tokai University School of Medicine (Isehara). The findings were published in October 2014 by the ‘Journal of Stroke and Cerebrovascular Disorders’. During their study, the Tokai researchers evaluated 77 CAS procedures, which were performed consecutively with IVUS between May 2008 and December 2012. All cases were distally protected with filter devices. The rate of PP was assessed at the end of each procedure using IVUS and angiography.
Six plaque protrusions (7.8%) through the stent struts were detected by IVUS but only two (2.6%) by angiography. One of the major predictors of PP was pre-procedural severe stenosis with flow delay.   Overall stroke rate was 2.6% (major 0%, minor 2.6%), and these occurred in the catheterization laboratory. However, no late stroke was observed at 30 days after procedure.
One of the key outcomes of the Tokai study was that IVUS seems to detect plaque protrusion better than angiography. Since the adequate management of plaque protrusion is considered as a means to reduce stroke complications, IVUS usage is worth considering.

The Yao-Nara study
In 2017, results of another, broader Japanese effort by researchers at Ishinkai Yao General Hospital (Yao) and Nara Medical University (Nara) suggested different conclusions. The study, which was published in the April 17 issue of ‘JACC: Cardiovascular Interventions’, sought to clarify the frequency and prognosis of plaque protrusions in CAS by analysing data on 328 patients treated under IVUS guidance in the period 2007-2016, using different types of stents and embolic protection devices.
At 30 days, the rate of ipsilateral ischemic stroke was 2.8% and the rate of transient ischemic attack was 2.6%. There were no patient deaths. Moreover, in most stroke cases, symptoms were observed immediately after dilatation.  New ischemic lesions were found in 35.7% of patients within 48 hours of the procedure, based on diffusion-weighted imaging (DWI).

Lack in lesion variation, but stent type matters, as does evaluation method
One of the most intriguing conclusions was the lack of difference in the incidence of new ischemic lesions, in terms of stable versus unstable plaques. Analysis by stent type, however, did indicate difference. There were more ipsilateral ischemic lesions with open-cell stents as compared to closed-cell stents.
The authors suggest the findings indicate a necessity to minimize PP “to prevent periprocedural ischemic stroke” and that the placement of open-cell stents with high radial force may disintegrate unstable plaque, causing protrusions. One strategy mentioned by the authors to manage PP is to perform IVUS to check for large-volume protrusions. The latter are then sought to be differentiated as being either ‘convex’ or ‘non-convex’. For the former, stent-in-stent placement is performed using closed-cell stents until the disappearance of the protrusion. In the case of ‘nonconvex’ protrusions, the authors recommend 5-10 minutes of observation, followed again by stent-in-stent placement should the protrusion enlarge, or clinical follow-up within 30 days after CAS in case of no enlargement.

As we observed previously, there are differences in PP incidence based on whether it is evaluated by angiography or IVUS. One of the most significant limitations of the Japanese study above was the occurrence of 27 cases of plaque protrusion on IVUS, but just nine cases on angiography. The study protocol required confirmation by both modalities.

Limitations to Yao-Nara study
In an editorial accompanying the study, William A. Gray, MD (Lankenau Heart Institute, Wynnewood, PA), cautioned that this two thirds difference “will clearly affect many of the subsequent associations and conclusions.” Gray also underlined that by treating plaque protrusion with stent-in-stent placement in approximately half of the cases, the researchers might have potentially changed the clinical and imaging outcomes. Furthermore, he cautioned, the study was not core-lab controlled, with no routine use of MRI before and after procedures, and that the assessors were not blinded. Finally, they did not mandate use of specific stents or perform independent neurological assessment of clinical outcomes.
As a result, the association between stent type and plaque protrusion is ‘likely’. However, it may not be as strong as the authors contend.

Such shortcomings are likely to be addressed when the Japanese effort is paired with emerging data showing reductions in both plaque protrusion and ischemic lesions via the use of mesh-covered stents. Gray agrees that this is strengthening the case for “improvements in stent design.” Indeed, emerging micromesh stent designs are expected to contribute greatly to prevention of plaque protrusion and may become a new standard for CAS.

SCAFFOLD trial
In the United States, the SCAFFOLD trial, led by Peter A. Schneider, MD, of Kaiser Foundation Hospital at Honolulu (Hawaii) is completing evaluation of a mesh-covered, open-cell heparin coated stent in patients at high surgical risk. The objectives are to make the first 30 days safer, with the understanding that reduced cell size equates to less plaque prolapse and fewer delayed events.
Other similar trials using different mesh technologies are also under way, and more are imminent. In Italy, for instance, University of Roma La Sapienza has begun a positive-control study to analyze and compare the rate of off-table subclinical neurological events in two groups of patients submitted to CAS with a close-cell stent, and a new mesh-covered carotid stent called C-Guard.
Overall, new parameters are coming into place, via stents with differences in pore size, flexibility etc. The drivers for such efforts range from new materials to a broad range of cardiovascular conditions. In France, for example, University Hospital Grenoble is conducting trials with Mguard, a stainless-steel closed cell stent covered with an ultra-thin polymer mesh sleeve, to prevent distal embolization during percutaneous coronary intervention in ST-segment-elevation myocardial infarction.

Case selection and stenting success

One of the observations of SCAFFOLD was that case selection for stenting was a key “to good clinical results.”
So far, patient selection criteria for CAS is largely based on surgical risk related to other co-morbidities. The morphology of the atherosclerotic plaque is given little attention, although studies have demonstrated the existence of extensive variability, which in turn confers specific risks for plaque vulnerability. Overall, the detection of unstable plaque on MR plaque imaging and the use of open cell stent are considered to be significant predictive factors of PP.

In recent years, there have been growing calls for devising best practices in peri-procedural management and follow-up, and for continuous feedback from clinicians to industry to improve stent design.
In general, achieving better outcomes of CAS is seen as the best method to solidify its place as a frontline treatment of carotid vascular disease. 

One promising approach for patient selection and identification of plaque, has been the use of virtual histology intravascular ultrasound imaging (VH IVUS). Researchers have suggested a strong correlation between VH IVUS plaque characterization and the true histological examination of plaque following endarterectomy, especially in ‘vulnerable’ plaque types.
The results of one of the earliest efforts in this area were published in October 2007 in ‘The Journal of Endovascular Therapy’. This followed a prospective, two-arm study by the Arizona Heart Hospital & Translational Research Center. The researchers enrolled 30 patients.
In the first arm of the study, 15 patients underwent VH IVUS examination of carotid plaque with a cerebral protection device. This was immediately followed by carotid endarterectomy (CEA), and the comparison of ‘virtual’ with true histology (classifying plaque type by VH IVUS and histopathology in a blinded study).
In the second arm, 15 patients undergoing CAS had a preliminary VH IVUS scan performed with cerebral protection. Debris collected from the filter following stenting was examined histologically and compared with the VH IVUS data.
The diagnostic accuracy of VH IVUS to agree with true histology in different carotid plaque types was 99.4% in thin-cap fibroatheroma, 96.1% for calcified thin-cap fibroatheroma, 85.9% in fibroatheroma, 85.5% for fibrocalcific, 83.4% in pathological intimal thickening, and 72.4% for calcified fibroatheroma.

https://interhospi.com/wp-content/uploads/sites/3/2020/08/IH145_thematic_crop.jpg 300 800 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:17:292021-01-08 12:30:34Carotid artery stenting – the challenge of plaque protrusion
Page 92 of 103«‹9091929394›»

Latest issue of International Hospital

April 2024

12 December 2025

New imaging framework transforms epilepsy surgery planning

11 December 2025

AI achieves superhuman accuracy in blood cell classification using generative diffusion models

11 December 2025

Siemens Healthineers unveils AI-powered imaging chain

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The medical devices information portal connecting healthcare professionals to global vendors

Sign in for our newsletter
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Media kit
    • Submit Press Release

Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@interhospi.com

PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Sign in for our newsletter

Free subscription